Navigation Links
OncoGenex Pharmaceuticals Added to Russell Indexes
Date:6/30/2009

OGX-011 agreement to provide OncoGenex with sole rights to OGX-011 and sole responsibility for development and related costs and partnering decisions, subject to financial obligations to Isis. OncoGenex is also solely responsible for development and related costs and partnering decisions regarding OGX-427 and OGX-225. Key intellectual property related to OGX-011, OGX-427 and OGX-225 were discovered by the University of British Columbia and the Vancouver Prostate Centre, and were exclusively licensed to OncoGenex.

More information about OncoGenex is available at www.oncogenex.com.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoGenex Pharmaceuticals Files Shelf Registration Statement
2. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
3. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
4. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
5. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
6. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
7. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
8. OncoGenex Reports First Quarter Financial Results
9. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
10. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
11. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic ... it has received a $1.5M Phase II SBIR ... to further develop its therapeutic agent to reduce ... need in end stage renal disease (ESRD) patients ... National Institute of Diabetes and Digestive and Kidney ...
(Date:8/26/2015)... KONG , Aug. 26, 2015 China ... China,s leading provider of cord ... stem cell storage services, today announced that the Company ... Limited ("MO2"), an entity wholly owned by Mr. Yuen ... Company, has acquired the outstanding shares (the "Shares") of  ...
(Date:8/26/2015)... ... 2015 , ... PRC Clinical, a Clinical Trial Management Expert CRO, ... in southern California. The Clinical Trial Management Expert CRO seeks to introduce more California-based ... , Stem Cell Meeting on the Mesa on October ...
(Date:8/25/2015)... UK (PRWEB) , ... August 25, 2015 , ... ... determining whether breast tissue lesions are cancerous is described by University of Illinois ... international society for optics and photonics. , In “ Breast cancer diagnosis using ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 4
... SEATTLE, Nov. 10, 2010 Dendreon Corporation (Nasdaq: ... has completed the submission of the post-approval supplement ... the Morris Plains, New Jersey manufacturing facility. Dendreon ... to manufacture PROVENGE. The standard U.S. Food and ...
... announces that a new stem cell gene and enzyme replacement ... with Tay-Sachs disease on November 2, 2010. Tay-Sachs is a ... heritage and in very rare cases families of Eastern European ... appear normal at birth but about six months of age ...
... SAN DIEGO, Nov. 10, 2010 SG Biofuels , ... Jatropha, today announced it has established a strategic partnership with ... Limited (NYSE: BG ), to research and develop ... SG Biofuels President and Chief Executive Officer ...
Cached Biology Technology:Dendreon Submits Post-Approval Supplement to the PROVENGE Biologics License Application for New Jersey Manufacturing Facility 2Tay-Sachs Disease Stem Cell Gene Enzyme Treatment 2SG Biofuels and Bunge Form Strategic Alliance to Process Jatropha Seeds Into Sustainable Crude Oil 2
(Date:8/6/2015)... Aug. 6, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced collaboration with Microsoft on ... 10. Microsoft leveraged Synaptics, deep expertise in human ... Through stringent testing, Synaptics, advanced ... with Microsoft,s Precision TouchPad (PTP) specification empowering OEMs ...
(Date:8/5/2015)... 2015 Transparency Market Research has ... - Global Industry Analysis, Size, Share, Growth, Trends and ... recognition is forecast to reach US$ 2,671.8 Mn by ... surveillance systems by civil and government agencies. This is ... terrorist activities across the globe that would elevate the ...
(Date:8/4/2015)... DUBLIN , Aug. 04, 2015 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/nvh7k2/digital_forensics ) has announced the addition ... Component (Hardware, Software, and Service), Sub-Segment (Computer ... Cloud Forensics), Tool Types, Service, Vertical and ... report to their offering. By ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... A protein known to be overly active in ... to change the structural composition of mammary tissue, potentially ... from the Lombardi Comprehensive Cancer Center at Georgetown University ... Endocrine Society in Washington, DC, the scientists report that ...
... anymore waiting in the dark at this campus bus shelter. ... of engineering researchers at McMaster University has been installed to ... researchers are also hoping that the prototype will help boost ... is located on the west side of University Avenue between ...
... in new grants to study the use and impacts of ... viewed as a worrisome source of water and air pollution ... most important and least publicized environmental issues we face: Escaped ... water, and soil and has huge potential to contribute to ...
Cached Biology News:Protein linked to change in tissue that surround and support breast tumors 2Flexible solar strips light up campus bus shelter 2UC Davis begins $2.8 million in studies of agricultural nitrogen's impacts 2UC Davis begins $2.8 million in studies of agricultural nitrogen's impacts 3
Rabbit polyclonal to ErbB 2 (phospho Y1248) ( Abpromise for all tested applications). entrezGeneID: 2064 SwissProtID: P04626...
...
... Plus Western Blot Strong Antibody Stripping Solution ... Western blots that have been developed with ... It is not recommended for stripping colorimetric ... is not possible to effectively remove substrates ...
... 100 ml supplied as a 5x ... antibodies from membrane-bound proteins without destroying ... chemiluminescent or radioisotopic signals from blots. ... blots. Supplied as a 5X solution ...
Biology Products: